Multistep Chromatography for Extracellular Vesicle Purity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for preparing extracellular vesicles (EVs) face challenges in achieving high purity and scalability due to heterogeneity and complexity, leading to inefficiencies in therapeutic applications, particularly in removing nucleic acid impurities and achieving targeted drug delivery.
Innovation Solution
A multistep enzymatic and chromatographic method involving contact with a chromatography resin and a nuclease wash buffer containing a nuclease and a cation to reduce residual nucleic acid molecules, utilizing various chromatography resins such as cation exchange and anion exchange resins, to enhance EV purity and scalability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If current purification methods are used, then EV preparation is simple, but nucleic acid impurities are not sufficiently removed
Solution Approach 1:
The purification process is divided into multiple sequential steps: initial EV isolation, chromatography separation, and nuclease treatment. Each step targets specific impurities, with the nuclease step specifically addressing nucleic acid contamination. This segmented approach achieves high purity while maintaining manageable process complexity through modular design.
Solution Approach 2:
A nuclease enzyme is introduced as an intermediary agent to specifically degrade nucleic acid impurities. The nuclease acts as a mediator between the EV preparation and the purification goal, selectively removing DNA and RNA contaminants without affecting the EV structures themselves, thereby achieving high purity through a targeted biochemical intervention.
2Productivity
If traditional purification methods are used, then the process is straightforward, but scalability is limited
Solution Approach 1:
The chromatography resin and nuclease treatment protocol are designed to be universally applicable across different EV production scales. The same purification principles and reagents can be used whether producing small batches for research or large volumes for therapeutic applications, enabling scalable production while maintaining consistent purity standards through standardized procedures.
3Productivity
If EVs are produced at large scale, then therapeutic applications are enabled, but heterogeneity increases
Solution Approach 1:
The purification process utilizes controlled changes in physical and chemical parameters during chromatography separation, including gradient elution conditions and buffer composition adjustments. These parameter changes enable resolution of EV subpopulations based on their distinct properties, maintaining compositional uniformity even when processing large volumes that would otherwise increase heterogeneity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method significantly reduces nucleic acid impurities, improving the purity and uniformity of EVs, enabling their effective use in therapeutic applications by achieving high EV concentrations with reduced residual DNA levels.
Implementation Method 1
contacting the chromatography resin with a nuclease wash buffer; wherein the nuclease wash buffer comprises a nuclease
Implementation Method 2
contacting the sample with a chromatography resin
Implementation Method 3
contacting the sample with a chromatography resin
Implementation Method 4
the nuclease wash buffer comprises a nuclease and a cation
Data Source
AI summary
The present disclosure relates to multistep chromatographic methods for preparing extracellular vesicles (EVs). The methods were demonstrated to be effective in preparing high quality EVs in a large scale. The methods enable preparation of EVs for therapeutic and diagnostic applications, and isolation and/or sub-fractionation of EVs with desired properties for specific use.